C. Tracey Lancaster

Statistics

Publications

Citations

H-Index

Active since

2003

Affiliations

GlaxoSmithKline (United States)(Current)

Research Triangle Park Foundation

Orlando Immunology Center

C. Tracey Lancaster is an author at GlaxoSmithKline (United States) specializing in antiviral pharmacotherapy, antiretroviral therapy, and antiviral therapy.

Publications per year

2003–2010

Publications

Plasma Amprenavir Pharmacokinetics and Tolerability following Administration of 1,400 Milligrams of Fosamprenavir Once Daily in Combination with either 100 or 200 Milligrams of Ritonavir in Healthy Volunteers

Peter Ruane, Andrew Luber, Mary Beth Wire et al. · Antimicrobial Agents and Chemotherapy · 2007 · 29 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Comparison of Once-Daily Fosamprenavir Boosted with Either 100 or 200 mg of Ritonavir, in Combination with Abacavir/Lamivudine: 96-Week Results from COL100758

Charles B. Hicks, Edwin DeJesus, Louis Sloan et al. · AIDS Research and Human Retroviruses · 2009 · 21 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Impact of Low Abundance HIV Variants on Response to Ritonavir-Boosted Atazanavir or Fosamprenavir Given Once Daily with Tenofovir/Emtricitabine in Antiretroviral-Naive HIV-Infected Patients

Lisa Ross, Winkler G. Weinberg, Edwin DeJesus et al. · AIDS Research and Human Retroviruses · 2010 · 11 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients

Jeffrey P. Nadler, Joseph Gathe, Richard B. Pollard et al. · BMC Infectious Diseases · 2003 · 11 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +15

1–4 of 4